The remodeling of TME by the local combination therapy elicited a systemic anti-tumor response, supported by the increased numbers of tumor cell-specific T cells in TdLNs capable of producing IFNγ upon re-encounter with cancer cells. The gene discussed is IFNG; the disease is cancer.